Alitretinoin
Alitretinoin
Definition
An orally- and topically-active naturally-occurring retinoic acid with antineoplastic, chemopreventive, teratogenic, and embryotoxic activities. Alitretinoin binds to and activates nuclear retinoic acid receptors (RAR) and retinoid X receptors (RXR); these activated receptors act as transcription factors, regulating gene expression that results in the inhibition of cell proliferation, induction of cell differentiation, and apoptosis of both normal cells and tumor cells.
Also known as 3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)2-trans-4-trans-6-cis-8-trans-nonatetraenoic Acid, 9-cis Retinoic Acid, 9-cis-RA, 9-Cis-Retinoic Acid, 9-cRA, ALITRETINOIN, ALRT 1057, ALRT-1057, ALRT1057, LGD 1057, LGD-1057, LGD1057, Panretin, Panretyn, Panrexin, Retinoicacid-9-cis — per NCIT
Also identified as
- ATC D11AH04 per RXNORM
- ATC L01XF02 per RXNORM
- NCIT NCIT:C1574 per NCIT
- SCTID 116086005 per RXNORM
- SCTID 409488005 per RXNORM
- UNII 1UA8E65KDZ per RXNORM
Indications
| Disease | Relation | Source |
|---|---|---|
| Kaposi's sarcoma | may treat | MEDRT · Public domain (U.S. Government work) |
| Skin disorder | may treat | MEDRT · Public domain (U.S. Government work) |
Organ Effects
| Organ | Side effect / interaction | Source |
|---|---|---|
| Blood vessel | may treat a disease of this organ | DERIVED · CC BY 4.0 |
1 entry above is marked DERIVED: Atlas Médico inferred it by combining two sourced claims, and no source asserts this link directly. Treat it as a navigation aid, not as a clinical statement.